DT-EQUIPMENT
DT Equipment ehf. (DTE) (www.dtequipment.com ), a leader in real-time intelligence from liquid metals and developer of next-generation analytics for metals production and processing, is pleased to announce the appointment of Mr. Diego Areces as Chief Commercial Officer (CCO). His hire marks the latest in a series of appointments designed to further strengthen the DTE executive team and ensure that the company has the strategic, commercial and technical capabilities required for the next stage of its growth.
Commenting on the new appointment, Karl Matthiasson, CEO of DTE said, “I am very pleased to welcome Diego to our expanding executive team. His vast industry knowledge and extensive commercial experience will be indispensable, and we are delighted to have him on board as we continue the next stage of our journey.”
Mr. Areces who has 25 years’ experience in the industrial automation field, joins DTE to lead its commercial activities after a long tenure at Schneider Electric, where he held the position of Industrial Automation Networks Leader, Mining, Minerals, and Metals President and Process Automation North Asia Hub Leader, responsible for driving growth, transformation, and innovation. He will focus on bringing DTE’s breakthrough innovations in the metals analytics field to market and developing strategic relationships with customers and significant stakeholders.
“I am thrilled to join DTE, a great team of talented professionals on its way to transform a whole industry thanks to its breakthrough innovation", added Mr. Areces, “It is clear from my decades of working in the metals processing field that DTE’s real-time analytics and intelligence capabilities represent a significant breakthrough which offers a genuine opportunity to transform the way producers operate. I am focused on maximizing growth, value, sustainability, safety, and efficiency for all stakeholders, developing strategic relationships, and deploying business-driven technology and innovation; I look forward to an exciting new phase where there are no limits to what we can accomplish.
Mr. Areces is one of the early precursors of Industry 4.0, leading the deployment of internet technologies in industrial devices during the early 2000s. He has been a safety and sustainability champion and a significant contributor to the digital transformation of global industrial customers.
Mr. Areces is a founding member of modbus.org, was a marketing chair of the Interface for Distributed Automation (IDA) organization and a member of the Development Partner Institute for Mining. He holds an MS in Electronic Engineering from the University of Buenos Aires, Argentina, and a CSS in Administration and Management from Harvard University, US.
Find out more about DTE’s real-time liquid metals intelligence solutions at www.dtequipment.com
###
About DT Equipment
DTE, based in Reykjavik, Iceland, is a leading innovator in the field of real-time intelligence from liquid metals, helping customers to maximize value, efficiency, safety and sustainability. DTE’s vision is to transform metals production and processing with next-generation sensors and analytics, driving digital transformation of the metals industry towards Industry 4.0, while contributing to the 1.5-degree challenge.
DTE’s solution range combines first-in-industry LP-LIBS™ (Liquid-Phase Laser-Induced Breakdown Spectroscopy) elemental analysis with a powerful machine learning cloud platform, delivering valuable intelligence and predictive insights from liquid metals across the entire value chain.
For more information, please visit www.dtequipment.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210215005203/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom